This compound serves as a key intermediate in medicinal chemistry, particularly in the synthesis of targeted cancer therapies such as tyrosine kinase inhibitors (TKIs). Featuring a quinazoline core substituted with a 3-chloro-2-fluorophenyl amino group at position 4, a methoxy group at 7, and an acetate at 6, it is used in the development of drugs that target enzymes involved in cell growth signaling pathways. These inhibitors can block tyrosine kinases to halt cancer cell proliferation, showing promise for treating cancers like non-small cell lung cancer. Its structure facilitates further derivatization, such as deprotection and addition of side chains, to produce more effective anticancer agents.